News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Raymond James reiterated a Market Perform rating on Bristol-Myers Squibb (NYSE:BMY), stating that recent ZEPHYR trial data for ML-007C-MA does not pose a risk to Cobenfy and confirms its strong position in schizophrenia treatment. The firm believes Cobenfy has a significant commercial and clinical …
Sharemaestro market context Trend signal active 52 weeks +19.5%Bristol Myers Squibb (NYSE:BMY) recently hit a new 52-week high of $63.24, trading around $63.07, and has a market capitalization of approximately $128.1 billion. Analyst sentiment is mixed, with 8 buys, 10 holds, and 1 sell rating, and an average price target of $61.25, …
Bristol Myers Squibb (BMS) has launched Relopduo, a fixed-dose combination for unresectable or metastatic melanoma, in India. This drug, which combines nivolumab and relatlimab, is the first FDA-approved FDC of two immune checkpoint inhibitors. Priced at ₹2,99,900 per vial, it offers a new treatment …
Theo Ai has appointed Sandra Leung, former Executive Vice President and General Counsel of Bristol Myers Squibb, to its Board of Directors, enhancing the company's governance and strategic direction. Leung's extensive experience in litigation, corporate governance, and risk management will help tailor Theo Ai's …
Theo Ai has appointed Sandra Leung, former EVP and General Counsel of Bristol Myers Squibb, to its board of directors. Leung previously served on Theo Ai’s General Counsel Advisory Board and brings over 30 years of corporate legal experience, including expertise in litigation risk …
BMO Capital has reiterated its Market Perform rating and $60.00 price target for Bristol-Myers Squibb (NYSE: BMY), citing the competitive advantage of its schizophrenia drug, Cobenfy. This follows a failed Phase 2 trial for a competing drug, ML-007C-MA, which did not meet statistical significance. …
Bristol-Myers Squibb (BMY) stock recently hit a new 52-week high of $62.89, trading at $62.95 with a market capitalization of $127.94 billion. The company has maintained dividend payments for 56 consecutive years, currently yielding 4.06%. This milestone follows the FDA's acceptance of their New …
This article provides a detailed overview of Bristow Group Inc (VTOL), a provider of vertical flight solutions. It covers the company's business scope, financial data including market cap and P/E ratio, and lists key executives along with their shareholdings. The report also touches upon …
Bristow Group Inc (SWB:ERG1) generated 1.27 billion EUR in revenue last year. The majority of this revenue, 843.31 million EUR, came from its Offshore Energy Services segment. The United Kingdom was the largest regional contributor, accounting for 350.80 million EUR.
Bristol-Myers Squibb Company (HAM:BRM) generated €41.03 billion in revenue last year, primarily from its Innovative Medicines segment. This marks a decrease from the previous year's €46.66 billion. The United States was the largest contributor to revenue, accounting for €28.33 billion.
The article provides an earnings forecast for Bristow Group Inc (VTOL), highlighting its current earnings forecast score of 8.00 and an average price target of $45.00. Based on four analysts, the stock receives a "Buy" rating with a potential upside of 34.58%. The company's …
This article provides a brief overview of Bristol-Myers Squibb Company's Celgene Contingent Value financials, specifically focusing on its revenue breakdown for the Innovative Medicines segment and geographical contributions. Last year, the company generated $48.19 billion USD from Innovative Medicines, with the largest portion, $33.28 …
This article provides a brief overview of Bristow Group Inc. (VTOL) stock, including its current price, market performance, and key financial metrics. It shows the stock trading at $45.50, down 1.32%, and lists data such as its P/E ratio, market capitalization, and dividend yield. …
Bristol-Myers Squibb (BMY) has initiated a first-in-human Phase 1 trial for BMS-986533, an oral drug, to evaluate its safety, pharmacokinetics, and dosing in healthy volunteers. This randomized, double-blind, placebo-controlled study includes multiple dosing schemes and assesses interactions with common medications. The trial, which began …
Oak Associates Ltd. OH has acquired a new position in Bristol Myers Squibb Company, purchasing 131,790 shares valued at approximately $8.0 million during the first quarter. Bristol Myers Squibb reported strong quarterly earnings, beating analyst estimates for both EPS and revenue, and announced a …
Sei Investments Co. increased its stake in Bristol Myers Squibb (NYSE:BMY) by 8.2% in the first quarter, bringing its total holdings to over 2.19 million shares valued at $133 million. Several other institutional investors also adjusted their positions in BMY. Analysts have a mixed …
BMY added 5.5% in the latest week and led its US Drug Manufacturers - General group, but Sharemaestro Market Dynamics have not fully confirmed the move.
A consortium has launched Project SEAN to further electric aviation in Scotland's Highlands and Islands. This initiative was reported as a key newswire event, particularly relevant to Bristow Group Inc. (VTOL), and was alerted to Quantisnow Plus members shortly after publication. The project aims …
Bristol Myers Squibb (BMY) saw a 1.05% gain, closing at $61.40, while the broader market declined. The stock has increased by 10.47% over the past month, outperforming both the Medical sector and the S&P 500. Analysts anticipate an 8.9% year-over-year earnings growth for its …
This article provides a risk profile for the Bristow Group Inc. 6.875% 01-MAR-2028 bond, identified by FINRA VTOL5129959. It offers an overview of the bond's characteristics, including coupon and redemption details, and highlights key metrics for assessing credit risk. The content indicates that the …
Bristow-led Project SEAN has secured £1.5 million from the UK Department for Transport to conduct electric aircraft demonstration flights across Scotland's Highlands and Islands starting in 2027. The three-month program will use BETA Technologies' ALIA CTOL (CX300) aircraft to gather operational data, assess infrastructure, …
The U.S. Department of Labor filed an amicus brief supporting Bristol-Myers Squibb in an appeal, arguing that retirees lack Article III standing to sue over pension risk transfers if they continue to receive full benefits. This action, along with a similar brief for Lockheed …
This GuruFocus page provides 30-year financial data for Bristow Group Inc (NYSE: VTOL), including its stock price, market capitalization, enterprise value, and various financial ratios. It details growth rates for revenue, EPS, EBIT, EBITDA, and book value, along with tools for detailed financial analysis, …
Bristol Myers Squibb Co. (BMY) shares rose by 1.23% on Thursday, closing at $61.51, despite a general market downturn where the S&P 500 and Dow Jones Industrial Average both fell. The stock, however, still underperformed compared to some competitors and ended 2.19% below its …
Sharemaestro market context Trend signal active 52 weeks +58.2% · Next-week setup positive 55.1%Bristol Myers Squibb (BMY) is expected to report a year-over-year increase in earnings despite lower revenues for the quarter ended June 2026, with Wall Street anticipating $1.59 EPS on $11.67 billion in revenue. The company has a Zacks Earnings ESP of +0.51% and a …
Sharemaestro market context Trend signal active 52 weeks +58.2% · Next-week setup positive 55.1%The U.S. Department of Labor has filed an amicus brief supporting Bristol-Myers Squibb in a pension risk transfer (PRT) appeal, joining business groups, insurers, and states. They argue that retirees lack Article III standing as they still receive full benefits and that allowing such …
Bristol-Myers Squibb (BMY) has gained momentum following FDA acceptance of its New Drug Application for mezigdomide and an AI collaboration with Nvidia for drug discovery. The company is currently considered 3.2% undervalued with a fair value of $62.96, despite existing risks related to patent …
Sharemaestro market context Trend signal active 52 weeks +19.5%This article summarizes Bristow Group's 2026 Annual General Meeting (AGM), held virtually on June 3, 2026. Key outcomes included the confirmation of a quorum, the absence of shareholder proposals, and the nomination of nine individuals for election to the board until the 2027 annual …
Bristol Myers Squibb (BMY) has opened a significant 427,000 square foot R&D hub in San Diego, integrating NVIDIA-powered AI infrastructure to accelerate drug discovery. This initiative aims to enhance the speed and efficiency of its oncology, cardiovascular, and immunology programs, potentially offsetting patent expiries …
Washington University in St. Louis and Bristol Myers Squibb have initiated a multiyear collaboration to foster scientific exchange and advance drug development in neuroscience. This partnership will provide WashU medical and research trainees with opportunities to work alongside Bristol Myers Squibb scientists and will …
A recent lobbying disclosure reveals that Bristol-Myers Squibb Company (BMY) reported $3,160,000 in lobbying expenditures for Q2 2026, addressing issues such as drug pricing, intellectual property reform, and the Inflation Reduction Act. The article also details recent congressional stock trading, insider transactions, hedge fund …
Sharemaestro market context Trend signal active 52 weeks +58.2% · Next-week setup positive 55.1%Bristol Myers Squibb plans to construct "the most powerful AI factory in life sciences" with Nvidia's assistance, marking its expanded collaboration to enhance AI capabilities for complex pharmaceutical problems. Meanwhile, Samsung Biologics is moving to acquire PolyPeptide Group for approximately $1.8 billion, a strategic …
Bristol Myers Squibb is expanding its computing infrastructure by deploying a second NVIDIA DGX SuperPOD built on DGX Vera Rubin NVL72 systems, which provides ten times greater performance per megawatt and will significantly accelerate drug discovery. This investment extends an existing three-year partnership with …
Search by ticker symbol or company name and select a result to open its chart.